Ulfo Luca, Costantini Paolo Emidio, Di Giosia Matteo, Danielli Alberto, Calvaresi Matteo
Dipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.
Dipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy.
Pharmaceutics. 2022 Jan 20;14(2):241. doi: 10.3390/pharmaceutics14020241.
The epidermal growth factor receptor (EGFR) plays a pivotal role in the proliferation and metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are hallmarks of many human malignancies. As such, EGFR-targeted therapies hold significant potential for the cure of cancers. In recent years, photodynamic therapy (PDT) has gained increased interest as a non-invasive cancer treatment. In PDT, a photosensitizer is excited by light to produce reactive oxygen species, resulting in local cytotoxicity. One of the critical aspects of PDT is to selectively transport enough photosensitizers to the tumors environment. Accordingly, an increasing number of strategies have been devised to foster EGFR-targeted PDT. Herein, we review the recent nanobiotechnological advancements that combine the promise of PDT with EGFR-targeted molecular cancer therapy. We recapitulate the chemistry of the sensitizers and their modes of action in PDT, and summarize the advantages and pitfalls of different targeting moieties, highlighting future perspectives for EGFR-targeted photodynamic treatment of cancer.
表皮生长因子受体(EGFR)在癌细胞的增殖和转移中起关键作用。EGFR表达和激活的异常是许多人类恶性肿瘤的标志。因此,针对EGFR的疗法在癌症治疗方面具有巨大潜力。近年来,光动力疗法(PDT)作为一种非侵入性癌症治疗方法越来越受到关注。在光动力疗法中,光敏剂被光激发产生活性氧,从而导致局部细胞毒性。光动力疗法的关键方面之一是将足够的光敏剂选择性地转运到肿瘤环境中。因此,已经设计出越来越多的策略来促进针对EGFR的光动力疗法。在此,我们综述了最近的纳米生物技术进展,这些进展将光动力疗法的前景与针对EGFR的分子癌症治疗相结合。我们概述了光敏剂的化学性质及其在光动力疗法中的作用模式,并总结了不同靶向部分的优点和缺陷,强调了针对EGFR的癌症光动力治疗的未来前景。